



DTAus - ASM

Date: Friday 7 October 2022

Time: 9:15AM-5:00PM

Location: Sydney University NSW

Conference Program

Alzheimer's Research is our best answer

Time	Topic
9:15 - 10:00am	Registration/Welcome Tea & Coffee
10:00 - 10:15am	Conference Opening Dr Chrys Pulle & Maree McCabe CEO Dementia
10:15 – 11:00am	COVID and Cognition- double jeopardy A/Prof Michael Woodward
11:00 – 11:30am	Alzheimer's Dementia Trials Update 2022 A/Prof Roger Clarnette
11:30am-12:15pm	PET and blood biomarkers in clinical trials - competitive or complimentary? Prof Chris Rowe
12:15 - 1:00pm	LUNCH
1:00 - 1:15pm	Dementia Trials Australia 2022 AGM
1:15 – 1:45pm	Going private: Navigating the complexities and finding solutions A/Prof Kathryn Goozee
1:45 - 2:15pm	Can we attack brain amyloid more effectively? Roche A/Prof Michael Woodward
2:15 - 2:30pm	Tricaprilin - Driving brain metabolism to improve cognition. A new mode of action for Alzheimer's Disease, Cerecin Dr Lars Nelleman
2:30 – 3:00pm	Looking AHEAD – Eisai Dementia Research Update Prof Bruce Brew
3:00 – 3:05pm	Caught in the Crossfire Margaret Morton
3:05 - 3:20pm	AFTERNOON TEA
3:20 - 3:35pm	Investigation of activating autophagy to treat Alzheimer's disease, Seelos A/Prof Tina Soulis
3:35 – 3:50pm	Alzheimer's Disease Clinical trials , a CRO perspective, NTA Dr Irene Kourtis
3:50 - 4:05pm	SAME – Targeting TAU hyperphosphorylation in Alzheimer's disease - An investigator initiated phase 2 trial in AD Dr Nawaf Yassi
4:05 – 4:35pm	Novo Nordisk/Evoke + Dr Peter Johannsen
4:35 – 5:00	Closing Remarks



DTAus

DTAus Chair

Dr Chrys Pulle

ChrysRanjeev.Pulle@health.qld.gov.au

DTAus Executive

Prof. Chris Rowe

Dr. Karyn Boundy

A/Prof. Michael Woodward

Prof. Phillip Morris

A/Prof. Roger Clarnette

A/Prof. Kathryn Goozee

Ms. Roseanne Hogarth

Dr. Cathy Short



[Registration Details](#)

DTAus Annual Scientific Meeting, University of Sydney,

7th October, 2022 - Face to Face Registration - \$200

<https://www.trybooking.com/CAQNN>

Dr Chrys Pulle MBBS FRACP

Geriatrician - Department of Internal Medicine, Geriatric and Rehabilitation Unit - The Prince Charles Hospital

- Dr Pulle is currently working in a clinical capacity as a Senior Staff Specialist / Geriatrician at The Prince Charles Hospital. Dr Pulle's interests include Dementia and Orthogeriatric care.
- Dr Pulle is a Geriatrician who has been managing patients in the Hip Fracture Unit at The Prince Charles Hospital since its establishment in 2010.
- Dr Pulle is also a Principal Investigator at The Prince Charles Hospital Internal Medicine and Dementia Research Unit. Over the last 15 years the Research Unit has provided evaluation, diagnosis and treatment recommendations, to patients and caregivers participating in Pharmaceutical Sponsored clinical drug trials with the most recent advances in possible new medications for various Dementia types.
- Dr Pulle is current Chair of Dementia Trials Australia.



Maree McCabe AM,

Chief Executive Officer Dementia Australia


- A recognised leader, Maree brings extensive experience and expertise to the health, mental health and aged care sectors.
- Her career accomplishments include leading the former federation of Alzheimer's Australia to unify and become Dementia Australia.
- Maree's vision led to the development of internationally recognised, cutting edge, dementia education tools using computer games, virtual reality, artificial intelligence and innovative apps.
- Maree is a member of commonwealth health and aged care sector committees, sector Boards and, a member of the Alzheimer's Disease International Asia Pacific Regional Committee and Chair of the Nominations Committee.
- On 14 June 2021 Maree was appointed a Member of the Order of Australia in the Queen's Birthday Honours for significant service to people living with Alzheimer's and Dementia, and to the aged care sector, and included in the COVID-19 Honour Roll for contribution in support of Australia's response to the COVID-19 pandemic.



A/Professor Michael Woodward AM MB BS MD FRACP

Head of Aged Care Research and Memory Clinic, Austin Health, Heidelberg, VIC.

- Associate Professor Michael Woodward is Head of Aged Care Research and the Memory Clinic at Austin Health in Melbourne, Victoria, and an Honorary Medical advisor for Dementia Australia. He is a specialist in geriatric medicine with major interests in the treatment of Alzheimer's disease (AD) and other dementias. He is Principal Investigator for numerous research trials of new therapies for AD and related disorders. He is Past President of the AC4R – the Australasian Consortium of Centres for Clinical Cognitive Research that brings together researchers into therapeutic agents for dementia. He was a member of the Alzheimer's Australia Victoria Board, being appointed their chief medical advisor and chairing their research foundation, which administers over \$2 million of research funding.
- Michael Woodward's publication record includes over 120 original research and review articles. He has been awarded his MD on the overlap between the dementia syndromes. More recent research interests have focussed on characterizing the frontal variant of Alzheimer's Disease. He is a Fellow of the Australian Association of Gerontology (AAG), the Australian and New Zealand Society for Geriatric Medicine, the Australian Wound Management Association (AWMA) and the Royal Australasian College of Physicians (RACP) and has long served each of these professional bodies, including becoming President of AWMA and AAG (Vic) and chairing the Committee for Physician Training that oversaw the training of all RACP trainees.



A/Professor Roger M Clarnette, MB BS PhD FRACP

Geriatrician in the Department of Community and Geriatric Medicine, Fremantle Hospital and Health Service, WA.

- Medical Director, Australian Alzheimer's Research Foundation.
- Clinical Associate Professor, Medical School, University of Western Australia.
- Senior Sessional Member, State Administrative Tribunal, WA.
- Deputy Head of Department, Geriatric Medicine, Fiona Stanley Fremantle Hospitals Group, Western Australia.



Professor Christopher Rowe BMBS, FRACP, MD, FAANMS

Director of Molecular Imaging Research at Austin Health and the University of Melbourne, VIC.

- Christopher Rowe is a nuclear medicine physician and neurologist, with over 20 years of experience in dementia research and patient care.
- He is the Principle investigator and Director of the Australian Dementia Network (ADNeT) established across the nation in late 2018 with funding from the Federal Government through the NHMRC National Institute of Dementia Research and philanthropic donors. His research focus is molecular brain imaging and blood biomarkers in neurodegenerative diseases, particularly Alzheimer's disease, for better understanding, earlier more accurate detection, and to facilitate development of early therapeutic interventions.
- He is a 2021 Highly Cited Researcher (top 1% world-wide for neuroscience) and has received international awards for his work including the US Society of Nuclear Medicine Kuhl-Lassen Award for Outstanding Contribution to Brain Imaging and the Christopher Clark Award for advancing human amyloid imaging.



Dr Cathy Short MBSc, MBBS, FRACP

Clinical Lead- Central Adelaide Local Health Network Memory Service and Memory Clinical Trials, SA.

- Dr Short graduated from the University of Adelaide Medical School in 1995 and received her FRACP in Neurology and General Medicine in 2003. She is currently a Consultant Neurologist for the Central Adelaide Local Health Network (CALHN) which encompasses both The Royal Adelaide and Queen Elizabeth Hospitals in South Australia. She is the Clinical lead for the multi-disciplinary CALHN Memory Service and Head of CALHN Memory Trials which runs across both hospital sites.
- She has a special interest in Behavioural Neurology and the Dementias as a group of disorders. She has been working as a Neurology Staff Specialist for 17 years and has been actively involved in more than 60 Clinical drug trials for Alzheimer's disease and other dementias over that time.



A/Prof Kathryn Goozee

Director/CEO KaRa Institute of Neurological Diseases Macquarie Park

- Hon Associate Professor, Faculty of Medicine and Health Science, Macquarie University, Sydney
- Kathryn has a PhD in Clinical Neuroscience which focused on the prevention of Alzheimer's disease, examining cognitive, neuroimaging, and blood biomarkers.
- Kathryn has a strong track record for establishing new models of service, including being one of Australia's first Nurse Practitioners in Australia specialising in dementia. As the Managing Director of KaRa MINDS, Kathryn leads up to 20 staff, including specialist clinicians and researchers who deliver some of the most promising pharmaceutical clinical trials available worldwide. Removing traditional barriers to assessment, the KaRa MINDS team promote the prevention and early detection of dementia through their Memory Clinic services. Utilising health, lifestyle, blood, and neuropathology biomarkers, the KaRa MINDS team work to find the best solution for people 'at risk' of dementia as well as for those already living with dementia.
- Kathryn has more than 35 publications in highly regarded journals, as well as having contributed to the book 'Understanding Alzheimer's Disease'.



Dr Lars Nelleman

Senior Medical Director, Singapore joined Cerecin Pte Ltd in 2019.

- In this role, Dr. Nelleman provides medical and scientific management of clinical trials and clinical research programs.
- Prior to joining Cerecin, Dr. Nelleman worked with Lundbeck as vice president and regional medical director, Asia Pacific for 15 years, based in Singapore. In that role, he initiated, executed, and oversaw numerous clinical trials in the region. All Lundbeck clinical trials were within the disease areas of neurology and psychiatry.
- Dr. Nelleman started his career in clinical research as active investigator during his residency five (5) years at various Copenhagen City University hospitals. Hereafter he joined the pharmaceutical industry, initially Novo Nordisk and later Lundbeck
- Dr. Nelleman has a degree in Medicine from Copenhagen University 1983



Prof Bruce Brew

Prof of Medicine – Sydney University

- Bruce Brew is a physician scientist who is Professor of Medicine (Neurology) at the University of New South Wales and University of Notre Dame,
- Director of the Peter Duncan Neurosciences Unit and the Neurosciences Program St Vincent's Centre for Applied Medical Research and neurologist at St Vincent's Hospital Sydney.
- He has a long standing interest in dementia at both basic science and clinical levels. He has been conducting trials in Alzheimer's disease for approximately 25 years.
- He has written over 400 papers and four books and over 20,000-30,000 citations (Scopus-Google Scholar).
- He has been on numerous international scientific committees and serves on the editorial boards of several journals.
- He has been a reviewer for NIH as well as other national funding bodies in various countries.
- In 2015 he was awarded an Order of Australia for his services to Neurology.



Margie Morton

Manager and Senior Clinical Research Coordinator for the Internal Medicine and Dementia Research Unit & QLD Medical Education Officer for Geriatric Medicine Advanced Training for Consultant Geriatricians

- Margie is a clinical nurse and graduated from the Princess Alexandra Hospital in 1994.
- She holds a Bachelor of Education, a Bachelor of Nursing Science, and holds a Graduate Diploma in Emergency Nursing.
- Margie won the ARCs Australian Clinical Trials Honour Roll Award in 2011 and The Prince Charles Hospital Nursing Excellence Award in 2016 for Research and in 2020 she was awarded the TPCH Research Support Award
- Margie has worked in the industry of clinical trials for the last 22 years and has over the years been appointed to various consultancy groups including NHMRC Standardisation of Forms Committee, ARCS Site Interest Area Committee, Qld Health Advisory Group for Single Ethical Review Process to name a few.
- Margie's clinical practice is in the field of dementia research.



A/Professor Tina Soulis

Alithia Life Sciences

- Dr Tina Soulis has over 28 years of working in the healthcare (pharmaceuticals and devices), biotechnology, academic research, clinical research and management sectors in senior roles including: CEO of a Contract Research Organization, Director of a successful ASX200 company, VP of Clinical Strategy and Development with an innovative biotechnology company and now, Founder and Director of her own clinical consultancy company. A dynamic and strategic leader, Tina has an extensive network of stakeholders all over the world and experience in many therapeutic areas across all phases on development.
- Passionate about mentoring future industry leaders and advocating for the Australian R&D community, Tina serves on several therapeutics executive advisory boards and advisors many US-based biotechnology companies.
- Recently, Tina launched her own consultancy, Alithia Life Sciences, where her motivation and mission is to work with her clients to deliver efficient accomplishment of their project, add value to their programs and to ultimately enable improvement of human health and wellbeing.
- Tina is also VP of Clinical Strategy and Development for Kinosis Therapeutics Pty Ltd, an innovative NIH/NIDA backed biotechnology company developing novel therapies for unmet neurological conditions.
- Previously, Tina was CEO for Neuroscience Trials Australia where she successfully grew the business on average 39% annually, thus forming a sustainable and world-respected organization.
- Tina is one of the few Australian clinical development leaders who has successfully taken products from lab to regulatory approval.



Dr Irene Kourtis PhD, GAICD, GDiplLaw

CEO Neuroscience Trials Australia

- Dr Kourtis is a highly regarded leader with board and executive level experience across NFP, government and private sectors. Irene has built a career within life science and service industries supporting clinical diagnostics, medical research, clinical genomics, and forensic medicine for improved health outcomes.
- This includes CEO / Managing Director of the Australian Genome Research Facility, member of the Melbourne Genomics Health Alliance, board member of the Forensic and Clinical Toxicology Association, COO of the Australian Academy of Science, Technology and Engineering, and Head of Enterprise and Business Development at the Victorian Institute of Forensic Medicine.
- With knowledge of technology, and innovation, Irene is successful in building organisational capability to deliver quality, contract services across biomedical, biotechnology, and pharma sectors.
- Irene has a track record of establishing world class infrastructure and supporting the translation of R&D into clinical application. Having led several 'growth through transformation strategies', Irene fosters positive relationships, actively builds partnerships and skilled in creating and securing business opportunities. Qualified with a PhD in Virology and post-doctoral research in the use of gene therapy to treatment glioblastomas at the Department of Surgery, the University of Melbourne. Complemented with a Graduate Diploma in Intellectual Property Law and a graduate of the Australian Institute of Company directors.



Dr Nawaf Yassi MBBS(Hons), BSc(Med), FRACP, PhD

Joint Laboratory Head (Watson/Yassi Lab) Population Health and Immunity Division

- Nawaf Yassi is a Neurologist at the Royal Melbourne Hospital.
- Joint lab head at the WEHI.
- Clinical and academic interests are in stroke and dementia. His work in dementia focuses on understanding the contribution of cerebrovascular disease to dementia clinical profiles, improved diagnosis using blood-based biomarkers, as well as exploring novel therapeutics through investigator initiated clinical trials.



Dr Peter Johannsen

International Medical Vice President, M&S, OSCD & Outcomes Clinical Drug Development

- Dr. Peter Johannsen is a board-certified neurologist with more than 25 years' experience in cognitive neurology and Alzheimer trials. He is an International Medical Vice President in Global Development of Novo Nordisk since February 2020.
- He has previously worked at the at the Memory Clinic and the Memory Research Group at the National Danish Dementia Research Centre, Copenhagen University Hospital, Denmark (www.videnscenterfordemens.dk).
- He was responsible for the clinical trial program on Alzheimer's disease and did clinical trials from phase I, first-in-human to phase III. Dr Johannsen received his medical degree from Aarhus University, Denmark in 1992 and defended his PhD thesis on 'PET scanning activation studies of attention modalities in patients with Alzheimer's disease' in 1999.
- He has published over 70 scientific papers and given more than 200 lectures and/or educational sessions focusing on the treatment of Alzheimer's disease.
- He has previously served as the vice-chairman of the Danish Alzheimer Association, and was a board member of the European Alzheimer's Disease Consortium (EADC) for 6 years.

